• Earlier this week, Elevance Health reaffirmed its 2026 earnings and benefit expense guidance and presented at Goldman Sachs’ 47th Annual Global Healthcare Conference in Miami, underlining its outlook for adjusted earnings of at least $26.75 per diluted share and a targeted benefit expense ratio near 90.2%.
• Investor attention has also been reinforced by a higher-than-anticipated Medicare Advantage payment update and Elevance Health’s inclusion among value investor Seth Klarman’s top stock picks, highlighting confidence in the company’s revenue scale, cost control and capital allocation discipline.
• Next, we’ll examine how the reaffirmed 2026 guidance and Medicare Advantage payment update may influence Elevance Health’s existing investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Elevance Health Investment Narrative Recap

To own Elevance Health, you need to be comfortable with a large, government-focused insurer that relies on disciplined pricing and tight cost control to manage volatile medical trends. The reaffirmed 2026 earnings and benefit expense guidance, together with the higher Medicare Advantage payment update, supports the near term earnings catalyst but does not remove the main risk that elevated medical costs in ACA and Medicaid could still pressure margins if trends worsen.

The reaffirmed 2026 outlook, including at least US$26.75 in adjusted EPS and a benefit expense ratio target near 90.2%, is the clearest signal in this news flow. It ties directly into the core catalyst of improving cost predictability through analytics, value based care and Carelon’s broader health services, while giving investors a reference point to judge whether those initiatives are offsetting ongoing medical cost and regulatory pressures.

Yet behind this reaffirmed guidance, there is still a material risk around persistent medical cost trends that investors should be aware of if...

Elevance Health's narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and a $2.0 billion earnings increase from $5.4 billion today.

Uncover how Elevance Health's forecasts yield a $387.85 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming earnings could reach about US$7.3 billion by 2029, but this latest guidance and Medicare Advantage update may either strengthen that optimistic case or highlight how exposed those assumptions are to elevated medical costs and policy shifts in the government book.

Explore 10 other fair value estimates on Elevance Health - why the stock might be worth 24% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.